Posted on

cbd for osteosarcoma

BOULDER, Colo. , September 13, 2018 /PRNewswire-PRWeb/ — At 16 years old, Braden Stevenson received a diagnosis of osteosarcoma, a malignant bone cancer, and immediately underwent surgery to amputate his leg and start chemotherapy. The medical test came in 6 months later on November 20, 2017 ; the cancer nodules moved to his lungs and increased to 40 and varied in size up to 8 mm. The doctors told Braden, and his mother, Amy Oliver , that there was little more they could do and the prognosis was grim. Not to give up on her son’s life the mother and son chose another option: a cancer protocol from Trill Alternatives, Boulder, CO , using THC/CBD and THCa.

A laboratory study of cannabidiol (CBD) in human glioma cells showed that when given along with chemotherapy, CBD may make chemotherapy more effective and increase cancer cell death without harming normal cells. Studies in mouse models of cancer showed that CBD together with delta-9-THC might make chemotherapy such as temozolomide more effective.

David Threlfall , the founder of Trill Alternatives, reached out and explained how Cannabis works in the body to create cell death or apoptosis.

Cbd for osteosarcoma

The invasive capacity of MG-63 cells was measured using a Transwell® chamber (Corning, NY, USA). All reagents and the Transwell® chamber were pre-incubated at 37°C. The suspension of exponentially growing MG-63 cells (2×10 5 cells/ml) was placed into the upper compartment in serum-free medium. Subsequently, 20 µM cannabinoid WIN-55,212-2, 20 µM ADM or ‘Cannabinoid + ADM’ were separately added into the upper compartments. The complete medium containing 10% FBS was placed into the lower compartment and served as chemoattractant. After 48 h of incubation at 37°C with 5% CO2, non-invading cells were removed using cotton swabs. Invading cells were fixed with 4% paraformaldehyde (Sigma-Aldrich) for 40 min, stained with 0.1% crystal violet (Sigma-Aldrich) for 30 min and counted in six random image fields by microscopy (TCS 4D; Leica Camera AG). The invasion rates were calculated as follows:

Osteosarcoma is a bone malignancy that predominantly affects children and adolescents, and exhibits high invasion and metastasis rates. It has been reported that the five-year survival rate of patients who suffer from this disease remains at only 20% due to a high rate of systemic spread at the early phase and the strong chemotherapy resistance of osteosarcoma (1). Although adriamycin (ADM) is an effective benchmark agent for the management of osteosarcoma, it also results in harmful side-effects including toxicity and chemoresistance that substantially affect the quality of life of patients (2–4). Therefore, novel therapeutic approaches and drugs must be sought for the treatment of osteosarcoma.

Invasion assay

Natural products which have potential antitumor activities have become a focus of attention for study in previous years (5,6). Cannabinoids, the active components naturally derived from the marijuana plant Cannabis sativa L., have been reported as potential antitumor drugs based on their ability to limit inflammation, cell proliferation and cell survival (7). To date, several cannabinoids have been identified and characterized, including Δ(9)-tetrahydrocannabinol (THC), cannabidiol, cannabinol (CBN) and anandamide, as well as synthetic cannabinoids, including WIN-55,212-2, JWH-133 and (R)-methanandamide (7). In the early 1970s, THC and CBN were shown to inhibit tumor growth in Lewis lung carcinoma (8). Subsequently, cannabinoids were found to induce apoptosis and inhibit the proliferation of various cancer cells, including those of glioma (9) and lymphoma (10), and prostate (11–13), breast (14), skin (15) and pancreatic cancer (13,16).


In which N (control) was the number of invading cells in the control group and N (treated) was the number of invading cells in the groups with cannabinoid and/or ADM treatment.